chartexchange

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire Inc. | Nov 16, 2026 7:15 AM EST

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

Read original article